menu search

DICE / Options Traders Blast Dice Therapeutics Stock After Buyout

Options Traders Blast Dice Therapeutics Stock After Buyout
Dice Therapeutics Inc (NASDAQ:DICE) was last seen up 37.6% to trade at a fresh all-time high of $46.56, after  Eli Lilly (LLY) revealed it will buy the immunology drug maker for roughly $2.4 billion , or $48 per share, in an all-cash deal that is a 40% premium to DICE's last close. Read More
Posted: Jun 20 2023, 10:33
Author Name: Schaeffers Research
Views: 111795

DICE News  

DICE Therapeutics (DICE) Up 37% on Buyout Offer from Eli Lilly

By Zacks Investment Research
June 21, 2023

DICE Therapeutics (DICE) Up 37% on Buyout Offer from Eli Lilly

DICE Therapeutics (DICE) is set to be acquired by pharma-giant Eli Lilly (LLY) in an all-cash transaction for $2.4 billion. The transaction will likel more_horizontal

ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics

By Zacks Investment Research
June 21, 2023

ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics

Eli Lilly (LLY) has agreed to acquire DICE Therapeutics (DICE) in a cash deal worth approximately $2.4 billion. This strategic move is part of Eli Lil more_horizontal

Is Eli Lilly's Dice Therapeutics Acquisition a Needle-Moving Event?

By The Motley Fool
June 21, 2023

Is Eli Lilly's Dice Therapeutics Acquisition a Needle-Moving Event?

Eli Lilly and Dice Therapeutics agreed to a $2.4 billion buyout on Tuesday. Lilly might have landed important new immunology drugs via this deal. more_horizontal

Eli Lilly's $2.4 Billion Acquisition of Dice Therapeutics: What Investors Need to Know

By The Motley Fool
June 20, 2023

Eli Lilly's $2.4 Billion Acquisition of Dice Therapeutics: What Investors Need to Know

Lilly plans to buy Dice Therapeutics for $2.4 billion to expand its immunology pipeline. Investors appear to approve of the deal's price tag. more_horizontal

Shares of Eli Lilly, Dice Therapeutics Gain on Acquisition Announcement

By GuruFocus
June 20, 2023

Shares of Eli Lilly, Dice Therapeutics Gain on Acquisition Announcement

Looking to enhance its product portfolio for immune-related diseases, an area where it has lagged behind the competition, Eli Lilly & Co. ( LLY , Fina more_horizontal

Eli Lilly Buys DICE Therapeutics for $2.4 Billion

By Investopedia
June 20, 2023

Eli Lilly Buys DICE Therapeutics for $2.4 Billion

Eli Lilly agreed to buy DICE Therapeutics for $2.4 billion. The deal values DICE shares at an almost 40% premium from Friday's close. more_horizontal

Why Shares of Dice Therapeutics Are Skyrocketing Tuesday

By The Motley Fool
June 20, 2023

Why Shares of Dice Therapeutics Are Skyrocketing Tuesday

Lilly is paying a 40% premium for Dice's shares. Dice is a clinical-stage biotech with six programs in its pipeline. more_horizontal

2 Biotech Stocks For Your June 2023 Watchlist

By Stockmarketcom
June 20, 2023

2 Biotech Stocks For Your June 2023 Watchlist

Biotech stocks to watch in the stock market now. more_horizontal


Search within

Pages Search Results: